Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for chronic central serous chorioretinopathy
IRCT20220122053792N1Phase 2Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Chronic central serous chorioretinopathy (CSCR) comparing Eplerenone with Placebo (2 arms). Primary endpoints: Best modified vision, Central macular thickness and 2 more. Started Jan 2022; status: completed.
02
Drugs
eplerenone
03
Conditions
Chronic central serous chorioretinopathy (CSCR)
Beyond the preview
Go deeper on IRCT20220122053792N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220122053792N1.